Compile Data Set for Download or QSAR
Report error Found 1370 Enz. Inhib. hit(s) with Target = 'High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A'
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484541(US10934294, Example 62 | US11028092, Example 63)
Affinity DataKi:  0.0100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484570(US10934294, Example 92 | US10934294, Example 91 | ...)
Affinity DataKi:  0.0100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484529(US10934294, Example 57 | US10934294, Example 56 | ...)
Affinity DataKi:  0.0100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484497(US10934294, Example 22 | US10934294, Example 21 | ...)
Affinity DataKi:  0.0100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484551(US10934294, Example 75 | US10934294, Example 74 | ...)
Affinity DataKi:  0.0200nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484573(US10934294, Example 94 | US11028092, Example 93)
Affinity DataKi:  0.0300nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726413(4-oxo-6-(2-(pyridin- 2-yl)cyclobutyl)-1- ((S)-1-(6...)
Affinity DataKi:  0.0340nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484596(US10934294, Example 114 | US11028092, Example 114)
Affinity DataKi:  0.0400nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484509(US10934294, Example 33 | US10934294, Example 32 | ...)
Affinity DataKi:  0.0400nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM502801(US11028092, Example 111)
Affinity DataKi:  0.0400nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484591(US10934294, Example 110 | US11028092, Example 110)
Affinity DataKi:  0.0500nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484539(US10934294, Example 61 | US10934294, Example 60 | ...)
Affinity DataKi:  0.0800nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484559(US10934294, Example 81 | US10934294, Example 80 | ...)
Affinity DataKi:  0.0900nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711677(US12187729, Example 28)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711694(US12187729, Example 45)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484489(US10934294, Example 14 | US10934294, Example 13 | ...)
Affinity DataKi:  0.100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484501(US10934294, Example 26 | US10934294, Example 25 | ...)
Affinity DataKi:  0.100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484484(US10934294, Example 6 | US11028092, Example 6)
Affinity DataKi:  0.100nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711680(US12187729, Example 31)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711696(US12187729, Example 47)
Affinity DataIC50: 0.100nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726423(6-(2-(5-fluoropyridin- 2-yl)cyclobutyl)-4- oxo-1-(...)
Affinity DataKi:  0.120nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484537(US10934294, Example 59 | US10934294, Example 58 | ...)
Affinity DataKi:  0.120nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484517(US10934294, Example 45 | US10934294, Example 44 | ...)
Affinity DataKi:  0.130nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484594(BDBM502802 | US10934294, Example 112)
Affinity DataKi:  0.130nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726435(6-(2-(1-methyl-1H- pyrazol-5- yl)cyclobutyl)-4- ox...)
Affinity DataKi:  0.145nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484542(US10934294, Example 97 | US10934294, Example 63 | ...)
Affinity DataKi:  0.150nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484583(US10934294, Example 105 | US10934294, Example 104 ...)
Affinity DataKi:  0.180nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484587(US10934294, Example 109 | US10934294, Example 108 ...)
Affinity DataKi:  0.200nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484480(US10934294, Example 2 | US11028092, Example 2)
Affinity DataKi:  0.200nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711695(US12187729, Example 46)
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484525(US10934294, Example 49 | US10934294, Example 48 | ...)
Affinity DataKi:  0.220nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484561(US10934294, Example 82 | US11028092, Example 82)
Affinity DataKi:  0.230nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484563(US10934294, Example 84 | US11028092, Example 84)
Affinity DataKi:  0.25nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726451(6-(2-(3-cyano-1H- pyrazol-1- yl)cyclobutyl)-4- oxo...)
Affinity DataKi:  0.256nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484595(US10934294, Example 113 | US11028092, Example 113)
Affinity DataKi:  0.270nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711678(US12187729, Example 29)
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM502780(US11028092, Example 90)
Affinity DataKi:  0.300nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711697(US12187729, Example 48)
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726447(6-(2-(4-cyano-1H- pyrazol-1- yl)cyclobutyl)-4- oxo...)
Affinity DataKi:  0.350nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726462(4-oxo-6-(2-(4- (trifluoromethyl)- 1H-pyrazol-1- yl...)
Affinity DataKi:  0.399nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

LigandPNGBDBM130711(US8822448, 23)
Affinity DataIC50: 0.400nMpH: 8.0Assay Description:The PDE9-inhibiting activity was measured by the following method. That is, to a buffer solution containing tris(hydroxymethyl)aminomethane-hydrochlo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2015
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711670(US12187729, Example 21)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711464(US12187729, Example 1)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711682(US12187729, Example 33)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484493(US10934294, Example 16 | US10934294, Example 18 | ...)
Affinity DataKi:  0.400nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726482(6-(2-(4-fluoro-1H- pyrazol-1- yl)cyclobutyl)-4- ox...)
Affinity DataKi:  0.402nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM726429(6-(2-(3-fluoropyridin- 2-yl)cyclobutyl)-4- oxo-1-(...)
Affinity DataKi:  0.461nMAssay Description:Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. Solutions of test compounds were prepar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
7/15/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM484505(US10934294, Example 30 | US10934294, Example 29 | ...)
Affinity DataKi:  0.5nMAssay Description:Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 μL. S...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM711676(US12187729, Example 27)
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of the representative compounds according to the present invention against phosphodiesterase 9A was tested based on the polar...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/20/2025
Entry Details
US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50651871(CHEMBL5641637)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of human PDE9A2 expressed in Sf9 cells using cGMP as substrate by scintillation proximity assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
Displayed 1 to 50 (of 1370 total ) | Next | Last >>
Jump to: